中国药房2017，Vol.28Issue(33)：4609-4613,5.DOI:10.6039/j.issn.1001-0408.2017.33.01
"获取基本药物"——第67届世界卫生大会我国国家提案介绍
"Access to Essential Medicine":Introduce of China's Proposal at the 67th World Health Assembly
摘要
Abstract
OBJECTIVE:To provide reference for the proper understanding of the content of"Access to Essential Medicine"resolution proposed by China at the 67th World Health Assembly(WHA),policy making and implication of the resolution in Chi-na. METHODS:Through descriptive analysis,the proposal background,approving process and resolution content of the"Access to Essential Medicines"resolution were introduced;the potential impact and effect of the resolution were analyzed. RESULTS:"Ac-cess to Essential Medicine"included"urging member states"and"requesting director-general",20 items."Urging member states"covered 11 items,including national medicine policy,essential medicine selection,medicine related health systems research,inter-national exchanges and cooperation,children's essential medicine accessibility,essential medicine related education,training and public recognition,obstacle recognition and strategy development,essential medicine management system and monitoring mecha-nism,flexible use of the existing policy."Requesting director-general"covered 9 items and put forward the support WHO needed to realize"urging member states"and effect evaluation after the resolution. CONCLUSIONS:"Access to Essential Medicine"is great significance to maintain human health,especially people's health in developing countries,safeguard the rights and interests of peo-ple's basic drug use and promote rational drug use. The approval of"Access to Essential Medicine"at WHA represents China's in-ternational discourse right on improving the basic medical service among basic population,and highlights China's magnitude of a great nation.关键词
基本药物/可及性/世界卫生大会/决议/国家提案Key words
Essential medicine/Accessibility/World Health Assembly/Resolution/State proposal分类
医药卫生引用本文复制引用
蒋璐灿,张伶俐,刘丹,曾力楠.."获取基本药物"——第67届世界卫生大会我国国家提案介绍[J].中国药房,2017,28(33):4609-4613,5.基金项目
国家卫生计生委药政司委托研究课题(No.药政2015〔27)号) （No.药政2015〔27）
